AR022886A1 - Utilizacion de xenon o mezclas de gas xenon composicion para el tratamiento de intoxicaciones neurologicas y procedimiento para la preparacion de un medicamento inhalable - Google Patents

Utilizacion de xenon o mezclas de gas xenon composicion para el tratamiento de intoxicaciones neurologicas y procedimiento para la preparacion de un medicamento inhalable

Info

Publication number
AR022886A1
AR022886A1 ARP000101053A ARP000101053A AR022886A1 AR 022886 A1 AR022886 A1 AR 022886A1 AR P000101053 A ARP000101053 A AR P000101053A AR P000101053 A ARP000101053 A AR P000101053A AR 022886 A1 AR022886 A1 AR 022886A1
Authority
AR
Argentina
Prior art keywords
xenon
neurological
treatment
intoxications
procedure
Prior art date
Application number
ARP000101053A
Other languages
English (en)
Original Assignee
Air Prod & Chem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7900688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR022886(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Air Prod & Chem filed Critical Air Prod & Chem
Publication of AR022886A1 publication Critical patent/AR022886A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilizacion de xenon o mezclas de xenon para el tratamiento de intoxicaciones neurologicas. Particularmente la invencion está destinada a la utilizacion dexenon en caso de intoxicaciones neurologicas causadas por un exceso de neurotransmisores. Elxe non disminuye la liberacion de neurotransmisores,particularmente dopamina, causadas por situaciones hipoxicas tales como isquemia o trauma craneano-cerebral. También en el caso de depresiones, esquizofrenia oenfermedad de Parkinson en que estápertur bado el equilibrio de neurotransmisores puede utilizarse terapéutica con xenon. La aplicacion es particularmentesencilla por inhalacion y la inocuidad del xenon está demostrada por su utilizacion como anestésico.
ARP000101053A 1999-03-11 2000-03-09 Utilizacion de xenon o mezclas de gas xenon composicion para el tratamiento de intoxicaciones neurologicas y procedimiento para la preparacion de un medicamento inhalable AR022886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19910986A DE19910986C2 (de) 1999-03-11 1999-03-11 Verwendung von Xenon bei der Behandlung von Neurointoxikationen

Publications (1)

Publication Number Publication Date
AR022886A1 true AR022886A1 (es) 2002-09-04

Family

ID=7900688

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101053A AR022886A1 (es) 1999-03-11 2000-03-09 Utilizacion de xenon o mezclas de gas xenon composicion para el tratamiento de intoxicaciones neurologicas y procedimiento para la preparacion de un medicamento inhalable

Country Status (29)

Country Link
US (3) US6559190B1 (es)
EP (1) EP1158992B2 (es)
JP (1) JP4954373B2 (es)
KR (1) KR100674407B1 (es)
CN (1) CN1170544C (es)
AR (1) AR022886A1 (es)
AT (1) ATE248599T1 (es)
AU (1) AU757361B2 (es)
BG (1) BG105889A (es)
BR (1) BR0010456A (es)
CA (1) CA2367136C (es)
CZ (1) CZ302864B6 (es)
DE (2) DE19910986C2 (es)
DK (1) DK1158992T3 (es)
EE (1) EE200100480A (es)
ES (1) ES2206202T5 (es)
HK (1) HK1048073B (es)
HU (1) HUP0201393A3 (es)
IL (2) IL145177A0 (es)
MD (1) MD2935C2 (es)
NO (1) NO20014379L (es)
PL (1) PL202941B1 (es)
PT (1) PT1158992E (es)
RS (1) RS49756B (es)
RU (1) RU2246949C2 (es)
SI (1) SI1158992T1 (es)
SK (1) SK285111B6 (es)
WO (1) WO2000053192A1 (es)
ZA (1) ZA200107291B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10045829A1 (de) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile Anästhesiemittel mit Xenon
DE10054563A1 (de) * 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
US20020102211A1 (en) * 2000-12-07 2002-08-01 Renshaw Perry F. Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
GB0209998D0 (en) † 2002-05-01 2002-06-12 Protexeon Ltd Use
GB0210021D0 (en) * 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
WO2003105871A1 (de) * 2002-06-12 2003-12-24 Messer Griesheim Gmbh Cerebrale protektion mit einem xenonhaltigen gas
CN1665542A (zh) * 2002-07-05 2005-09-07 梅瑟·格里斯海姆有限公司 含氙的佐剂
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7681572B2 (en) 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
US7337776B2 (en) 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
FR2858233B1 (fr) * 2003-07-30 2008-04-11 Air Liquide Sante Int Medicament gazeux inhalable a base de xenon et de protoxyde d'azote
BRPI0415232A (pt) * 2003-10-10 2006-12-12 Protexeon Ltd uso de xenÈnio com hipotermia para tratar asfixia neonatal
EP1675597A2 (en) * 2003-10-21 2006-07-05 Aga Ab Use of xenon for the prevention of programmed cell death
FR2863169B1 (fr) 2003-12-08 2006-02-10 Air Liquide Sante Int Medicament gazeux inhalable a base d'argon pour le traitement des neuro-intoxications
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
US7070005B2 (en) * 2004-02-10 2006-07-04 Planetair Turf Products, Llc Soil aerator assembly
WO2006017524A2 (en) * 2004-08-02 2006-02-16 Olney John W Preventing pathological increases in the rate of nerve cell suicide in immature nervous systems
WO2007075100A1 (en) * 2005-12-27 2007-07-05 Zakrytoe Aktsionernoe Obshchestvo 'atom-Med Center' Method for treating drug dependence
EP1980260A1 (en) * 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
CA2685446A1 (en) * 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
WO2010035074A1 (en) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Use of nitrous oxide, argon, xenon, helium, or neon, for the manufacture of a pharmaceutical composition for treating ischemic insults in patients who cannot be treated with thrombolytic agents
FR2952305B1 (fr) * 2009-11-10 2012-04-27 Air Liquide Medicament inhalable a base de xenon pour traiter ou pour prevenir les dyskinesies
WO2011081612A1 (ru) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Применение криптона или ксенона в качестве противовирусного средства
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
FR2960779A1 (fr) 2010-06-08 2011-12-09 Air Liquide Medicament gazeux inhalable a base de krypton contre les deficiences ou defaillances d'organes peripheriques
FR2964036B1 (fr) 2010-08-24 2013-04-12 Air Liquide Medicament gazeux inhalable a base de krypton pour le traitement des neuro-intoxications
WO2012109107A1 (en) 2011-02-07 2012-08-16 Rich Products Corporation Method for preserving cells and cell cultures
FR2975597B1 (fr) * 2011-05-24 2013-12-27 Air Liquide Utilisation de neon pour le traitement des neuro-intoxications, notamment des maladies enurodegeneratives et demyelinisantes
CN104114688B (zh) 2011-09-26 2016-08-31 先进保存技术股份有限公司 活组织保存的方法
RU2489154C1 (ru) * 2012-05-31 2013-08-10 Сергей Александрович Наумов Способ лечения вирусных гепатитов
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
FR2996459B1 (fr) * 2012-10-09 2015-02-06 Air Liquide Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996457B1 (fr) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Utilisation d'argon pour prevenir ou traiter les consequences neurologiques d'un choc septique
FR2996458B1 (fr) * 2012-10-09 2015-02-27 Air Liquide Utilisation de xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique
WO2014093277A1 (en) 2012-12-11 2014-06-19 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
JP6625966B2 (ja) 2013-03-15 2019-12-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 希ガスが豊富な液体ならびにその調製及び使用の方法
FR3007983B1 (fr) * 2013-07-08 2015-06-26 Air Liquide Association de xenon et d'un antagoniste des recepteurs nmda pour lutter contre une maladie neurodegenerative
FR3022456B1 (fr) * 2014-06-20 2016-07-15 Air Liquide Xenon associe a un antagoniste des recepteurs nmda pour lutter contre une proliferation tumorale dans le systeme nerveux central
FR3027226B1 (fr) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude Medicament pour traiter une maladie liee a un dysfonctionnement de la transmission synaptique dopaminergique
WO2016210144A1 (en) * 2015-06-23 2016-12-29 Bogin Vlad Therapeutic immune modulation using noble gas compositions
EP3373940A4 (en) * 2015-11-09 2019-10-02 The McLean Hospital Corporation METHODS AND COMPOSITIONS FOR THE PREVENTION OF SUICIDE, HOMICIDE AND SELF-TREATING BEHAVIORS
US20170341980A1 (en) * 2016-05-31 2017-11-30 Noblis Therapeutics, Inc. Noble gas neuroprotection and neuroregeneration from treatment related neurotoxicity
US10485825B2 (en) * 2016-08-29 2019-11-26 Nobilis Therapeutics, Inc. Prevention of pregnancy complications by noble gas administration
RU2019116383A (ru) * 2016-10-31 2020-11-30 Нобилис Терапьютикс, Инк. Лечение тревожных расстройств и усиление противотревожных воздействий с помощью применения смесей, содержащих инертный газ
CN107569509B (zh) * 2017-02-22 2018-09-21 滨州医学院 氙或氙气体混合物在制备治疗癫痫的制剂中的用途
CN108986622A (zh) * 2018-08-16 2018-12-11 广州迈普再生医学科技股份有限公司 一种颅内血肿微创穿刺清除术培训装置及其制备方法
RU2712804C1 (ru) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Способ коррекции функционального состояния человека в замкнутом пространстве

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5228434A (en) * 1991-07-16 1993-07-20 Praxair Technology, Inc. Mixture for anesthesia
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5357959A (en) * 1993-04-16 1994-10-25 Praxair Technology, Inc. Altered dipole moment magnetic resonance imaging method
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
IT1286058B1 (it) * 1996-10-29 1998-07-07 Siad Societa Italiana Acetilen Procedimento e apparecchiatura per la purificazione e recupero dello xeno e altri gas nobili in sistemi anestetici
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19823606C2 (de) * 1998-05-27 2002-02-28 Draeger Medical Ag Verwendung von Perfluorcarbone in einem Atemgasgemisch sowie die Vorrichtung
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
US20030180375A1 (en) 2003-09-25
MD2935C2 (ro) 2006-08-31
HUP0201393A3 (en) 2002-10-28
CN1359296A (zh) 2002-07-17
CA2367136A1 (en) 2000-09-14
NO20014379L (no) 2001-11-07
CZ20013234A3 (cs) 2002-06-12
NO20014379D0 (no) 2001-09-10
HK1048073B (zh) 2005-06-03
SK285111B6 (sk) 2006-06-01
DE60004974T3 (de) 2012-06-28
SK12792001A3 (sk) 2002-07-02
MD2935B2 (en) 2005-12-31
CN1170544C (zh) 2004-10-13
BG105889A (bg) 2002-04-30
WO2000053192A1 (en) 2000-09-14
ATE248599T1 (de) 2003-09-15
AU757361B2 (en) 2003-02-20
YU65401A (sh) 2004-07-15
HK1048073A1 (en) 2003-03-21
SI1158992T1 (en) 2004-02-29
PL350618A1 (en) 2003-01-27
DE60004974D1 (de) 2003-10-09
HUP0201393A2 (en) 2002-09-28
RS49756B (sr) 2008-04-04
DE19910986A1 (de) 2000-09-21
KR20010108338A (ko) 2001-12-07
CA2367136C (en) 2008-05-13
DK1158992T3 (da) 2003-12-29
MD20010349A (en) 2002-02-28
BR0010456A (pt) 2002-08-27
DE19910986C2 (de) 2001-06-07
JP2002538209A (ja) 2002-11-12
AU3287500A (en) 2000-09-28
RU2246949C2 (ru) 2005-02-27
PT1158992E (pt) 2004-01-30
EE200100480A (et) 2002-12-16
US8143317B2 (en) 2012-03-27
US20070110821A1 (en) 2007-05-17
ES2206202T5 (es) 2012-05-22
PL202941B1 (pl) 2009-08-31
EP1158992A1 (en) 2001-12-05
IL145177A (en) 2006-10-31
ES2206202T3 (es) 2004-05-16
ZA200107291B (en) 2003-02-26
US6559190B1 (en) 2003-05-06
EP1158992B1 (en) 2003-09-03
EP1158992B2 (en) 2012-02-01
DE60004974T2 (de) 2004-07-22
IL145177A0 (en) 2002-06-30
CZ302864B6 (cs) 2011-12-21
JP4954373B2 (ja) 2012-06-13
KR100674407B1 (ko) 2007-01-26

Similar Documents

Publication Publication Date Title
AR022886A1 (es) Utilizacion de xenon o mezclas de gas xenon composicion para el tratamiento de intoxicaciones neurologicas y procedimiento para la preparacion de un medicamento inhalable
MY134222A (en) NEW MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICALLY-EFFECTIVE COMPOUNDS AND ß-MIMETICS
IL163160A (en) Pharmaceuticals containing Formavertrol, Budsunida, 227hf 'pvp and peg for the treatment or relief of respiratory disorders
HN2001000008A (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
MY129422A (en) Medicinal compounds
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
SV2006002134A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis ref. 5195-sv
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
BR0209992A (pt) Inibidor de pde4 e um agente anticolinérgico em combinação para o tratamento de doenças obstrutivas das vias respiratórias
NZ605469A (en) Nalbuphine-based formulations and uses thereof
BRPI0514519A (pt) uso de xenÈnio como neuroprotetor em um indivìduo neonatal
BR112015019802A2 (pt) formulações farmacêuticas de nitrito e usos das mesmas
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
WO2008046407A3 (de) Verwendung von deuteriumdioxid zur behandlung von hyperproliferativen erkrankungen der haut
PT1220676E (pt) Prevencao do cancro colorrectal
PL1781292T3 (pl) Formulacja o przedłużonym uwalnianiu 3-amino-8-(1-piperazynylo)-2H-1-benzopiran-2-onu
UY27758A1 (es) Medicamento que contiene esteroides y un nuevo anticolinérgico
GT200500032A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior

Legal Events

Date Code Title Description
FC Refusal